- Top Meadow Farms world's first commercial adopter of vaccine -
BELLEVILLE, ON, Sept. 24 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its vaccine against E. coli O157:H7 in cattle has been used for the first time by a commercial beef producer. Top Meadow Farms, an Ontario-based producer of premium beef, integrated use of the E. coli O157:H7 vaccine into its Top in Field(TM) cattle rearing standards, under the auspices of Canadian Food Inspection Agency (CFIA) regulations governing the sale of the vaccine in Canada.
"Top Meadow is committed to producing beef that is of the best possible taste and healthfulness," stated Kym Anthony, owner of Top Meadow Farms. "The Bioniche vaccine provides an important pre-harvest intervention against E. coli O157:H7 that we are very pleased to add to our CFIA-audited Top in Field(TM) feed and husbandry protocols. Equally, we are pleased to have the support of retailers of our beef, such as the Highland Farms grocery chain and the award winning Via Allegro restaurant: All of us take food safety to be a core obligation."
"The adoption of our vaccine by Top Meadow Farms provides evidence that a beef producer recognizes the environmental and public health benefits that can result from reducing the shed of E. coli O157:H7 bacteria by cattle," said Graeme McRae, President & CEO of Bioniche Life Sciences Inc. "Shed bacteria can contaminate food, water and the environment, and human exposures to this pathogen result in an estimated 100,000 cases of illness per year in North America."
The vaccine remains under review by The Canadian Food Inspection Agency (CFIA) and The United States Department of Agriculture (USDA). In the course of its review process, the CFIA notified Bioniche last December that it was agreeable to issuing permits under the Permit to Release Veterinary Biologics regulations. These regulations allow cattle owners, through their veterinarians, to request vaccine be supplied to them by Bioniche.
Since that time, Bioniche has commenced production of the E. coli O157:H7 cattle vaccine at its Belleville, Ontario facility. This supply is now being provided to veterinarians requesting vaccine under the Canadian Permit to Release regulations. Bioniche will continue to scale up as full domestic and international approvals are received. Until such approvals are received, all vaccine will be shipped to Canadian veterinarians as permit requests are received and approved by the CFIA.
In order to progress from shipping under permits to a full license, the CFIA indicated that Bioniche was required to provide additional data confirming reduction in E. coli O157:H7 shedding by vaccinated animals. This information was provided to the CFIA in the spring and is currently under review.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary products for human and animal health markets worldwide. The fully-integrated company employs approximately 195 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop proprietary cancer therapies supported by revenues from marketed products in human and animal health. For more information, please visit http://www.Bioniche.com. For more information about E. coli O157:H7, please visit http://www.fightecoli.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2007 PR Newswire.
All rights reserved